Loring Wolcott & Coolidge Fiduciary Advisors LLP Madrigal Pharmaceuticals, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.2 Billion
- Q3 2025
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 500 shares of MDGL stock, worth $206,175. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$206,175% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
369Shares Held
23.3MCall Options Held
738KPut Options Held
473K-
Janus Henderson Group PLC London, X02.19MShares$904 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$862 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$822 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$815 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$774 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $7.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...